| scholarly article | Q13442814 |
| P356 | DOI | 10.1017/S1092852912000739 |
| P698 | PubMed publication ID | 23462201 |
| P50 | author | Stephen Stahl | Q24006564 |
| P2093 | author name string | Debbi A Morrissette | |
| P2860 | cites work | What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia | Q28185132 |
| Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis | Q28266069 | ||
| Effectiveness of antipsychotic drugs in patients with chronic schizophrenia | Q28273164 | ||
| Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. | Q30542486 | ||
| Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial | Q33383396 | ||
| Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings | Q33425487 | ||
| Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. | Q33814201 | ||
| 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). | Q34018491 | ||
| Antipsychotic dosing: how much but also how often? | Q34023214 | ||
| Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach | Q34127444 | ||
| Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia | Q34127541 | ||
| Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials | Q34160338 | ||
| A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting | Q34174609 | ||
| Gray matter in first-episode schizophrenia before and after antipsychotic drug treatment. Anatomical likelihood estimation meta-analyses with sample size weighting. | Q34415975 | ||
| Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial | Q34660553 | ||
| The CATIE schizophrenia trial: results, impact, controversy | Q34699698 | ||
| Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia | Q35855167 | ||
| Schizophrenia: from epidemiology to rehabilitation | Q36210656 | ||
| Adherence behaviour with psychotropic medication is a form of self-medication | Q36601408 | ||
| Partial compliance in schizophrenia and the impact on patient outcomes | Q37291965 | ||
| Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia | Q37348503 | ||
| Dopamine D2 receptors as treatment targets in schizophrenia | Q37774120 | ||
| Rethinking the role of long-acting atypical antipsychotics in the community setting | Q38031777 | ||
| Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study | Q38469670 | ||
| Prediction of a single psychotic episode: a 7.5-year, prospective study in first-episode psychosis. | Q39816531 | ||
| Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia | Q42632705 | ||
| Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia | Q42635940 | ||
| A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial | Q43008405 | ||
| Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder | Q43467235 | ||
| Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol | Q43733972 | ||
| Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment. | Q43762923 | ||
| One-year treatment continuation in patients prescribed risperidone long-acting injection in New Zealand: a retrospective study | Q43870857 | ||
| A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia | Q44044006 | ||
| Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia | Q44098132 | ||
| Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol | Q44538133 | ||
| Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes | Q44538134 | ||
| Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. | Q45218017 | ||
| A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study | Q46142676 | ||
| Direct transition to long-acting risperidone--analysis of long-term efficacy | Q46689236 | ||
| A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone | Q46973159 | ||
| From the World Health Organization. Mental health: new understanding, new hope | Q47573227 | ||
| Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study | Q47592542 | ||
| A prototype approach toward antipsychotic medication adherence in schizophrenia | Q47619156 | ||
| A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. | Q48350364 | ||
| Long-acting risperidone and oral antipsychotics in unstable schizophrenia | Q48900125 | ||
| Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. | Q51487290 | ||
| Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. | Q51900995 | ||
| A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. | Q55054009 | ||
| Mortality in Schizophrenia | Q58075292 | ||
| Why don't patients take their medicine? Reasons and solutions in psychiatry | Q58809499 | ||
| Brain Volume Changes After Withdrawal of Atypical Antipsychotics in Patients With First-Episode Schizophrenia | Q60610017 | ||
| How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia | Q73430973 | ||
| Effectiveness of switching antipsychotic medications | Q79411250 | ||
| One year outcome in first episode schizophrenia. Predictors of relapse | Q80358907 | ||
| Time course for antipsychotic treatment response in first-episode schizophrenia | Q83058853 | ||
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 10-21 | |
| P577 | publication date | 2012-11-01 | |
| P1433 | published in | C N S Spectrums | Q15750260 |
| P1476 | title | Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment | |
| P478 | volume | 17 Suppl 1 |
Search more.